Feb 10, 2026 (MarketLine via COMTEX) --
Aspire Biopharma announced it received notice from Nasdaq that it has regained compliance with the exchange's $1.00 minimum bid price requirement.
Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Company remains subject to an extension to evidence compliance with the $2.5 million stockholders' equity requirement.
The Company has made meaningful progress on its strategic plans for 2026 and expects to share additional details in the coming weeks. The Company believes that regaining compliance with this listing requirement positions it well for 2026.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
COMTEX_474923808/2227/2026-03-09T05:37:37
Copyright (C) 2026 Datamonitor. All rights reserved
